Two doses of COVID-19 vaccines from AstraZeneca and Pfizer-BioNTech have high effectivity in preventing hospitalization from the coronavirus’ Delta variant. The findings were made through a real-word study conducted by Public Health England. Out of 14,019 people who’d contracted the Delta variant, there was a 96% avoidance rate from those with two Pfizer jabs; 92% for those with two AstraZeneca jabs.
No deaths were recorded in the study, which included people who were hospitalized from the period of April 12 to June 4. In the case of single shots, Pfizer-BioNTech had a better response (94%) than AstraZeneca (71%) in hospitalization prevention. According to Pfizer CEO Albert Bourla, when variants began to emerge, their vaccines were tested against them.
The immunization chief of Public Health England, Mary Ramsay, M.D., has since issued a statement encouraging people to get both doses as soon as possible. “It is absolutely vital to get both doses as soon as they are offered to you, to gain maximum protection against existing and emerging variants.”